CDSCO Drug Alert: 48 drug samples flagged not of standard quality

Published On 2023-04-27 09:39 GMT   |   Update On 2023-04-27 09:39 GMT

In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has flagged 48 medicine batches for failing to qualify random drug sample test for the month of March-2023.These drugs samples include Telmisartan Tablets manufactured by Ridley Life Sciences, Domperidone Tablets manufactured by Karnataka Antibiotics &...

Login or Register to read the full article

In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has flagged 48 medicine batches for failing to qualify random drug sample test for the month of March-2023.

These drugs samples include Telmisartan Tablets manufactured by Ridley Life Sciences, Domperidone Tablets manufactured by Karnataka Antibiotics & Pharmaceuticals, Pioglitazone Hydrochloride Tablets manufactured by Skymap Pharmaceutical, Domperidone Tablets manufactured by Rivpra Formulation, Gabapentin Tablets manufactured by Synokem Pharmaceuticals and Mascot Health Series, Rolled Bandage (Non Sterilized, Size 15cm x 4 mts manufactured by Disha Surgicals, Dactinomycin for Injection USP 0.5 mg by Celon Laboratories, Iron and Folic Acid Tablets I.P. manufactured by Nestor Pharmaceuticals and others.

For more details, check out the link given below:

CDSCO Drug Alert: 48 Drug Samples Flagged Not Of Standard Quality


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News